Compare NXTC & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXTC | COCH |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 20.4M |
| IPO Year | 2019 | N/A |
| Metric | NXTC | COCH |
|---|---|---|
| Price | $13.24 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $23.00 | $9.50 |
| AVG Volume (30 Days) | 53.1K | ★ 514.3K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $208,000.00 |
| Revenue This Year | N/A | $3.66 |
| Revenue Next Year | N/A | $31.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.69 | $0.64 |
| 52 Week High | $15.74 | $2.32 |
| Indicator | NXTC | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 53.38 |
| Support Level | $9.21 | $0.66 |
| Resistance Level | $14.35 | $0.87 |
| Average True Range (ATR) | 1.26 | 0.07 |
| MACD | 0.35 | 0.02 |
| Stochastic Oscillator | 69.38 | 75.56 |
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.